On Monday, Celldex Therapeutics Inc (NASDAQ: CLDX) was -4.16% drop from the session before settling in for the closing price of $21.17. A 52-week range for CLDX has been $14.40 – $47.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 6.91% over the last five years. When this article was written, the company’s average yearly earnings per share was at -40.83%. With a float of $64.51 million, this company’s outstanding shares have now reached $66.38 million.
The firm has a total of 186 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.62%, operating margin of -2873.52%, and the pretax margin is -2366.07%.
Celldex Therapeutics Inc (CLDX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Celldex Therapeutics Inc stocks. The insider ownership of Celldex Therapeutics Inc is 2.84%, while institutional ownership is 109.39%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares.
Celldex Therapeutics Inc (CLDX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.47% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
You can see what Celldex Therapeutics Inc (CLDX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 21.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 178.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -4.02 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Analysing the last 5-days average volume posted by the [Celldex Therapeutics Inc, CLDX], we can find that recorded value of 1.08 million was better than the volume posted last year of 0.93 million. As of the previous 9 days, the stock’s Stochastic %D was 32.19%.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 59.26%, which indicates a significant increase from 14.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.97% in the past 14 days, which was lower than the 61.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.06, while its 200-day Moving Average is $24.31. Now, the first resistance to watch is $21.16. This is followed by the second major resistance level at $22.04. The third major resistance level sits at $22.53. If the price goes on to break the first support level at $19.79, it is likely to go to the next support level at $19.30. Should the price break the second support level, the third support level stands at $18.42.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
There are 66,384K outstanding shares of the company, which has a market capitalization of 1.35 billion. As of now, sales total 7,020 K while income totals -157,860 K. Its latest quarter income was 700 K while its last quarter net income were -53,800 K.
